{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:23Z","timestamp":1791765383132,"version":"4.3.4"},"reference-count":107,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jscai.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Society for Cardiovascular Angiography & Interventions"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jscai.2022.100513","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T05:42:36Z","timestamp":1666935756000},"page":"100513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-6038","authenticated-orcid":false,"given":"R. Wilson","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-7464","authenticated-orcid":false,"given":"Mario Enrico","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-0511","authenticated-orcid":false,"given":"Connie N.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jscai.2022.100513_bib1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jscai.2022.100513_bib2","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.jscai.2022.100513_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jscai.2022.100513_bib4","doi-asserted-by":"crossref","first-page":"e185239","DOI":"10.1001\/jamanetworkopen.2018.5239","article-title":"Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: a secondary analysis of the Euclid trial","volume":"1","author":"Gutierrez","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.jscai.2022.100513_bib5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1161\/CIRCRESAHA.121.318242","article-title":"Walking exercise therapy effects on lower extremity skeletal muscle in peripheral artery disease","volume":"128","author":"McDermott","year":"2021","journal-title":"Circ Res"},{"issue":"23","key":"10.1016\/j.jscai.2022.100513_bib6","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/CIRCULATIONAHA.121.055146","article-title":"Reduction in acute limb ischemia with Rivaroxaban versus placebo in peripheral artery disease after lower extremity revascularization: insights from VOYAGER PAD","volume":"144","author":"Hess","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jscai.2022.100513_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1253\/circj.CJ-16-1286","article-title":"Pathophysiology of intermittent claudication in peripheral artery disease","volume":"81","author":"Hamburg","year":"2017","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.jscai.2022.100513_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCULATIONAHA.119.040672","article-title":"Microvascular disease, peripheral artery disease, and amputation","volume":"140","author":"Beckman","year":"2019","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jscai.2022.100513_bib9","doi-asserted-by":"crossref","first-page":"e015451","DOI":"10.1161\/JAHA.119.015451","article-title":"Underuse of cardiovascular medications in individuals with known lower extremity peripheral artery disease: HCHS","volume":"9","author":"Hua","year":"2020","journal-title":"SOL. J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jscai.2022.100513_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1358863X19871100","article-title":"Trends in statin utilization among adults with severe peripheral artery disease including critical limb ischemia in an integrated healthcare delivery system","volume":"25","author":"Reynolds","year":"2020","journal-title":"Vasc Med"},{"issue":"11","key":"10.1016\/j.jscai.2022.100513_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","article-title":"Peripheral arterial disease detection, awareness, and treatment in primary care","volume":"286","author":"Hirsch","year":"2001","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jscai.2022.100513_bib12","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1161\/CIRCRESAHA.121.318243","article-title":"Racial and ethnic disparities in peripheral artery disease","volume":"128","author":"Hackler","year":"2021","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.jscai.2022.100513_bib13","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life\u2019s Essential 8: updating and enhancing the American Heart Association\u2019s construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jscai.2022.100513_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.atherosclerosis.2018.05.049","article-title":"Risk of peripheral artery disease according to a healthy lifestyle score: the PREDIMED study","volume":"275","author":"L\u00f3pez-Laguna","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jscai.2022.100513_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.avsg.2017.04.030","article-title":"Impact of nutritional state on critical limb ischemia early outcomes (DENUCRITICC study)","volume":"45","author":"du Mont","year":"2017","journal-title":"Ann Vasc Surg"},{"issue":"1","key":"10.1016\/j.jscai.2022.100513_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jvs.2014.10.022","article-title":"Advancing beyond the \u2018heart-healthy diet\u2019 for peripheral arterial disease","volume":"61","author":"Nosova","year":"2015","journal-title":"J\u00a0Vasc Surg"},{"issue":"9","key":"10.1016\/j.jscai.2022.100513_bib17","doi-asserted-by":"crossref","first-page":"e0184914","DOI":"10.1371\/journal.pone.0184914","article-title":"The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) study","volume":"12","author":"Tibuakuu","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jscai.2022.100513_bib18","doi-asserted-by":"crossref","first-page":"e010674","DOI":"10.1161\/JAHA.118.010674","article-title":"Cigarette smoking and subclinical peripheral arterial disease in blacks of the Jackson Heart Study","volume":"8","author":"Clark","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jscai.2022.100513_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jvs.2005.03.024","article-title":"Smoking and the patency of lower extremity bypass grafts: a meta-analysis","volume":"42","author":"Willigendael","year":"2005","journal-title":"J\u00a0Vasc Surg"},{"issue":"7","key":"10.1016\/j.jscai.2022.100513_bib20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/89961","article-title":"Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis","volume":"7","author":"Heeschen","year":"2001","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jscai.2022.100513_bib21","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/ATVBAHA.111.227124","article-title":"Acrolein inhalation prevents vascular endothelial growth factor-induced mobilization of Flk-1+\/Sca-1+ cells in mice","volume":"31","author":"Wheat","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.jscai.2022.100513_bib22","first-page":"146","article-title":"The cardiovascular effects of marijuana: are the potential adverse effects worth the high?","volume":"116","author":"Subramaniam","year":"2019","journal-title":"Mo Med"},{"issue":"9","key":"10.1016\/j.jscai.2022.100513_bib23","doi-asserted-by":"crossref","first-page":"e014570","DOI":"10.1161\/JAHA.119.014570","article-title":"Alterations in vascular function associated with the use of combustible and electronic cigarettes","volume":"9","author":"Fetterman","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jscai.2022.100513_bib24","first-page":"H1040","article-title":"Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation","volume":"275","author":"Moreno","year":"1998","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.jscai.2022.100513_bib25","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jvs.2014.08.064","article-title":"Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease","volume":"60","author":"Armstrong","year":"2014","journal-title":"J\u00a0Vasc Surg"},{"issue":"suppl 6","key":"10.1016\/j.jscai.2022.100513_bib26","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/bjs.1800691309","article-title":"The measured effect of stopping smoking on intermittent claudication","volume":"69","author":"Quick","year":"1982","journal-title":"Br J Surg"},{"key":"10.1016\/j.jscai.2022.100513_bib27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.18332\/tid\/146567","article-title":"Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial","volume":"20","author":"T\u00f8nnesen","year":"2022","journal-title":"Tob Induc Dis"},{"issue":"4","key":"10.1016\/j.jscai.2022.100513_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/ejvs.2002.1611","article-title":"The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT)","volume":"23","author":"Youssef","year":"2002","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"2","key":"10.1016\/j.jscai.2022.100513_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jscai.2022.100513_bib30","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"9326","key":"10.1016\/j.jscai.2022.100513_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jscai.2022.100513_bib32","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.jscai.2022.100513_bib33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","article-title":"Association of statin dose with amputation and survival in patients with peripheral artery disease","volume":"137","author":"Arya","year":"2018","journal-title":"Circulation"},{"issue":"41","key":"10.1016\/j.jscai.2022.100513_bib34","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1093\/eurheartj\/ehu080","article-title":"Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry","volume":"35","author":"Kumbhani","year":"2014","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.jscai.2022.100513_bib35","doi-asserted-by":"crossref","first-page":"e021412","DOI":"10.1161\/JAHA.121.021412","article-title":"Efficacy and safety of vorapaxar by intensity of background lipid-lowering therapy in patients with peripheral artery disease: insights from the TRA2P-TIMI 50 trial","volume":"10","author":"Gilchrist","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"25","key":"10.1016\/j.jscai.2022.100513_bib36","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jscai.2022.100513_bib37","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jscai.2022.100513_bib38","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: Odyssey OUTCOMES trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jscai.2022.100513_bib39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jscai.2022.100513_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jscai.2022.100513_bib41","article-title":"Benefits of icosapent ethyl in patients with prior peripheral artery disease: REDUCE-IT PAD","volume":"144","author":"Bhatt","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jscai.2022.100513_bib42","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jscai.2022.100513_bib43","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jscai.2022.100513_bib44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1358863X09360579","article-title":"Effect of niacin ER\/lovastatin on claudication symptoms in patients with peripheral artery disease","volume":"15","author":"Hiatt","year":"2010","journal-title":"Vasc Med"},{"issue":"9677","key":"10.1016\/j.jscai.2022.100513_bib45","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jscai.2022.100513_bib46","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","article-title":"Contemporary medical management of peripheral artery disease","volume":"128","author":"Bonaca","year":"2021","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.jscai.2022.100513_bib47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/ATVBAHA.119.312859","article-title":"Microvascular disease increases amputation in patients with peripheral artery disease","volume":"40","author":"Behroozian","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"10.1016\/j.jscai.2022.100513_bib48","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jscai.2022.100513_bib49","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jscai.2022.100513_bib50","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jscai.2022.100513_bib51","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jscai.2022.100513_bib52","doi-asserted-by":"crossref","first-page":"e008018","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","article-title":"Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: results from the EXSCEL trial","volume":"12","author":"Badjatiya","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.jscai.2022.100513_bib53","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","volume":"24","author":"Verma","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.jscai.2022.100513_bib54","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","article-title":"Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"issue":"18","key":"10.1016\/j.jscai.2022.100513_bib55","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study","volume":"42","author":"Paul","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jscai.2022.100513_bib56","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program","volume":"62","author":"Matthews","year":"2019","journal-title":"Diabetologia"},{"issue":"24","key":"10.1016\/j.jscai.2022.100513_bib57","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jscai.2022.100513_bib58","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jscai.2022.100513_bib59","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jscai.2022.100513_bib60","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","article-title":"Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jscai.2022.100513_bib61","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3-4","key":"10.1016\/j.jscai.2022.100513_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000520903","article-title":"Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials","volume":"107","author":"See","year":"2022","journal-title":"Pharmacology"},{"issue":"8","key":"10.1016\/j.jscai.2022.100513_bib63","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/clc.23843","article-title":"Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: insights from the TRA 2\u00b0 P-TIMI 50 trial","volume":"45","author":"Freedman","year":"2022","journal-title":"Clin Cardiol"},{"issue":"39","key":"10.1016\/j.jscai.2022.100513_bib64","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/eurheartj\/ehz687","volume":"40","author":"Grant","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jscai.2022.100513_bib65","article-title":"Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease","volume":"3","author":"Armstrong","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"9678","key":"10.1016\/j.jscai.2022.100513_bib66","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"7677","key":"10.1016\/j.jscai.2022.100513_bib67","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.jscai.2022.100513_bib68","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jscai.2022.100513_bib69","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2796.1990.tb00164.x","article-title":"Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study","volume":"227","author":"Janzon","year":"1990","journal-title":"J\u00a0Intern Med"},{"issue":"9038","key":"10.1016\/j.jscai.2022.100513_bib70","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Dennis","year":"1996","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jscai.2022.100513_bib71","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jscai.2022.100513_bib72","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/1358863X18775594","article-title":"Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: insights from the Euclid trial","volume":"23","author":"Berger","year":"2018","journal-title":"Vasc Med"},{"issue":"3","key":"10.1016\/j.jscai.2022.100513_bib73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.116.025880","article-title":"Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease","volume":"135","author":"Jones","year":"2017","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jscai.2022.100513_bib74","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.jscai.2022.100513_bib75","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.jscai.2022.100513_bib76","first-page":"1272","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"373","author":"Marciniak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.jscai.2022.100513_bib77","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.jscai.2022.100513_bib78","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jscai.2022.100513_bib79","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jscai.2022.100513_bib80","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2\u00b0 P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jscai.2022.100513_bib81","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1358863X19892690","article-title":"Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: analysis from the TRA 2 P-TIMI 50 trial","volume":"25","author":"Qamar","year":"2020","journal-title":"Vasc Med"},{"issue":"3","key":"10.1016\/j.jscai.2022.100513_bib82","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jscai.2022.100513_bib83","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jscai.2022.100513_bib84","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"20","key":"10.1016\/j.jscai.2022.100513_bib85","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial","volume":"71","author":"Anand","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jscai.2022.100513_bib86","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.11.050","article-title":"Long-term outcomes and associations with major adverse limb events after peripheral artery revascularization","volume":"75","author":"Hess","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9201","key":"10.1016\/j.jscai.2022.100513_bib87","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jscai.2022.100513_bib88","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"53","author":"Belch","year":"2011","journal-title":"J\u00a0Vasc Surg"},{"issue":"9","key":"10.1016\/j.jscai.2022.100513_bib89","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy\u2014the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.jscai.2022.100513_bib90","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1526602818760488","article-title":"Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial","volume":"25","author":"Moll","year":"2018","journal-title":"J\u00a0Endovasc Ther"},{"issue":"21","key":"10.1016\/j.jscai.2022.100513_bib91","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jscai.2022.100513_bib92","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2021.05.003","article-title":"Total ischemic event reduction with Rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial","volume":"78","author":"Bauersachs","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"39","key":"10.1016\/j.jscai.2022.100513_bib93","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1093\/eurheartj\/ehab408","article-title":"Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial","volume":"42","author":"Krantz","year":"2021","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.jscai.2022.100513_bib94","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.121.054835","article-title":"Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD trial","volume":"144","author":"Debus","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jscai.2022.100513_bib95","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2016.06.002","article-title":"Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries","volume":"179","author":"Jones","year":"2016","journal-title":"Am Heart J"},{"issue":"23","key":"10.1016\/j.jscai.2022.100513_bib96","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/CIRCULATIONAHA.120.050465","article-title":"Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety","volume":"142","author":"Hiatt","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jscai.2022.100513_bib97","first-page":"CD005262","article-title":"Pentoxifylline for intermittent claudication","volume":"10","author":"Broderick","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jscai.2022.100513_bib98","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1358863X07084910","article-title":"A\u00a0randomized trial of iloprost in patients with intermittent claudication","volume":"13","author":"Creager","year":"2008","journal-title":"Vasc Med"},{"issue":"11","key":"10.1016\/j.jscai.2022.100513_bib99","first-page":"e71","article-title":"AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.jscai.2022.100513_bib100","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1161\/CIR.0000000000000727","article-title":"Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: a science advisory from the American Heart Association","volume":"140","author":"Treat-Jacobson","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jscai.2022.100513_bib101","first-page":"CD005263","article-title":"Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication","volume":"4","author":"Hageman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"10.1016\/j.jscai.2022.100513_bib102","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2021.2536","article-title":"Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: the LITE randomized clinical trial","volume":"325","author":"McDermott","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jscai.2022.100513_bib103","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jacbts.2020.08.012","article-title":"Exercise training and revascularization in the management of symptomatic peripheral artery disease","volume":"6","author":"Biswas","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"10","key":"10.1016\/j.jscai.2022.100513_bib104","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2014.12.043","article-title":"Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study","volume":"65","author":"Murphy","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.jscai.2022.100513_bib105","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1001\/jama.2015.14851","article-title":"Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial","volume":"314","author":"Fakhry","year":"2015","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.jscai.2022.100513_bib106","doi-asserted-by":"crossref","first-page":"e010076","DOI":"10.1161\/JAHA.118.010076","article-title":"Underutilization of evidence-based Smoking Cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the international PORTRAIT registry","volume":"7","author":"Patel","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.jscai.2022.100513_bib107","doi-asserted-by":"crossref","first-page":"e007953","DOI":"10.1161\/CIRCOUTCOMES.121.007953","article-title":"Supervised exercise therapy for symptomatic peripheral artery disease among Medicare beneficiaries between 2017 and 2018: participation rates and outcomes","volume":"14","author":"Divakaran","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Journal of the Society for Cardiovascular Angiography & Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772930322005440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772930322005440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:29:37Z","timestamp":1762648177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772930322005440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2772930322005440"],"URL":"https:\/\/doi.org\/10.1016\/j.jscai.2022.100513","relation":{},"ISSN":["2772-9303"],"issn-type":[{"value":"2772-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the Society for Cardiovascular Angiography & Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jscai.2022.100513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of the Society for Cardiovascular Angiography and Interventions Foundation.","name":"copyright","label":"Copyright"}],"article-number":"100513"}}